IL197497A - Non-viral oligonucleotide transport systems - Google Patents

Non-viral oligonucleotide transport systems

Info

Publication number
IL197497A
IL197497A IL197497A IL19749709A IL197497A IL 197497 A IL197497 A IL 197497A IL 197497 A IL197497 A IL 197497A IL 19749709 A IL19749709 A IL 19749709A IL 197497 A IL197497 A IL 197497A
Authority
IL
Israel
Prior art keywords
delivery systems
viral delivery
oligonucleotide non
oligonucleotide
viral
Prior art date
Application number
IL197497A
Other languages
English (en)
Hebrew (he)
Other versions
IL197497A0 (en
Original Assignee
Fmc Biopolymer As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fmc Biopolymer As filed Critical Fmc Biopolymer As
Publication of IL197497A0 publication Critical patent/IL197497A0/en
Publication of IL197497A publication Critical patent/IL197497A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/87Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/722Chitin, chitosan
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5161Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
IL197497A 2006-09-15 2009-03-09 Non-viral oligonucleotide transport systems IL197497A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84472906P 2006-09-15 2006-09-15
PCT/EP2007/059740 WO2008031899A2 (en) 2006-09-15 2007-09-14 Oligonucleotide non-viral delivery systems

Publications (2)

Publication Number Publication Date
IL197497A0 IL197497A0 (en) 2009-12-24
IL197497A true IL197497A (en) 2013-06-27

Family

ID=39092312

Family Applications (1)

Application Number Title Priority Date Filing Date
IL197497A IL197497A (en) 2006-09-15 2009-03-09 Non-viral oligonucleotide transport systems

Country Status (9)

Country Link
US (1) US7875449B2 (enExample)
EP (1) EP2061516A2 (enExample)
JP (1) JP2010503640A (enExample)
KR (1) KR20090058562A (enExample)
CN (1) CN101588821A (enExample)
BR (1) BRPI0716925A2 (enExample)
CA (1) CA2662560A1 (enExample)
IL (1) IL197497A (enExample)
WO (1) WO2008031899A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2362376T3 (es) * 2006-07-07 2011-07-04 Aarhus Universitet Nanopartículas para la administración de ácido nucleico.
WO2010021720A1 (en) 2008-08-19 2010-02-25 Nektar Therapeutics Conjugates of small-interfering nucleic acids
WO2013059617A1 (en) * 2011-10-21 2013-04-25 Ndsu Research Foundation Liposome compositions and methods of use
DK2806896T3 (en) 2012-01-27 2018-03-05 Hoffmann La Roche Chitosan covalently bound to small molecule integrin antagonist for targeted delivery
KR101601035B1 (ko) 2013-02-28 2016-03-08 주식회사 종근당 키토산 및 액상결정 형성 물질을 포함하는 유전자 전달용 조성물
JPWO2017078054A1 (ja) 2015-11-04 2018-08-30 株式会社ステリック再生医科学研究所 RNAi分子とN−アセチル化キトサンとを含む複合体
WO2018216792A1 (ja) * 2017-05-26 2018-11-29 公益財団法人川崎市産業振興財団 血中におけるrnaの安定性の改善剤および投与方法
CN111568856B (zh) * 2020-06-24 2021-07-06 珠海舒桐医疗科技有限公司 一种阴道凝胶制剂及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3922260A (en) * 1973-08-24 1975-11-25 Quintin P Peniston Process for depolymerization of chitosan
US6184037B1 (en) 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
SE9904475D0 (sv) 1999-12-08 1999-12-08 Artursson Nucleic acid delivery system
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
NO317653B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som omfatter komplekser av kitosanoligomerer og nukleinsyre, fremgangsmate for a fremstille formuleringen samt anvendelser derav.
NO317654B1 (no) 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulering som inneholder en nukleinsyre og et kitosan, fremgangsmate for fremstilling av formuleringen, samt anvendelser derav.
FR2841137B1 (fr) * 2002-06-20 2004-08-13 Bioalliance Pharma Systeme de vectorisation comprenant des nanoparticules de taille homogene d'au moins un polymere et d'au moins un polysaccharide charge positivement
WO2004074314A2 (en) 2003-02-14 2004-09-02 University Of South Florida Chistosan-microparticles for ifn gene delivery
WO2005113770A1 (en) 2004-05-13 2005-12-01 Institut Gustave Roussy Anti-rhoa and -rhoc sirnas and therapeutic compositions comprising them.
US8399025B2 (en) * 2004-06-04 2013-03-19 Board Of Regents, The University Of Texas System Polyamine modified particles
CA2628313A1 (en) 2005-11-04 2007-05-31 Bio Syntech Canada Inc. Composition and method for efficient delivery of nucleic acids to cells using chitosan
US8846102B2 (en) * 2006-03-30 2014-09-30 Engene, Inc. Non-viral compositions and methods for transfecting gut cells in vivo
ES2362376T3 (es) * 2006-07-07 2011-07-04 Aarhus Universitet Nanopartículas para la administración de ácido nucleico.

Also Published As

Publication number Publication date
KR20090058562A (ko) 2009-06-09
US20080131371A1 (en) 2008-06-05
CA2662560A1 (en) 2008-03-20
IL197497A0 (en) 2009-12-24
CN101588821A (zh) 2009-11-25
EP2061516A2 (en) 2009-05-27
BRPI0716925A2 (pt) 2013-09-17
WO2008031899A3 (en) 2008-05-08
JP2010503640A (ja) 2010-02-04
US7875449B2 (en) 2011-01-25
WO2008031899A2 (en) 2008-03-20

Similar Documents

Publication Publication Date Title
IL192630A0 (en) Pesticide delivery system
GB2442875B (en) Regulated drug delivery system
GB2444395B (en) Delivery devices
GB2444394B (en) Delivery devices
IL197516A0 (en) Ester-based polymeric delivery systems
IL200077A0 (en) Transdermal delivery systems
IL198911A0 (en) Drug delivery
EP2029292A4 (en) DISTRIBUTION SYSTEM WITH SURPRISED SPONGE
EP2025123A4 (en) MULTICAST DELIVERY
PL2043543T3 (pl) Układ dostarczania energii
ZA201002122B (en) Vaginal delivery system
ZA201002014B (en) Drug delivery system
GB0707928D0 (en) Delivery system
EP2188002A4 (en) FLUID HANDLING SYSTEM
PL1896120T3 (pl) System dostarczania kontrastowego płynu
IL197497A0 (en) Oligonucleotide non-viral delivery systems
ZA200805986B (en) Pesticide delivery system
ZA201000215B (en) Sequential enzyme delivery system
GB2435420B (en) Delivery means
GB2468794B (en) Delivery devices
GB0709390D0 (en) Delivery means
EP2007465A4 (en) RADIONUCLEAR EQUIPMENT DELIVERY SYSTEM
ZA200803511B (en) Hydropower delivery system
GB0617616D0 (en) Message delivery system
GB0616952D0 (en) Delivery

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees